Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • AC Immune, Biogen deal

    AC Immune S.A., Lausanne, Switzerland Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Neurology The companies signed a three-year deal to develop and validate PET tracers for alpha-synuclein (SNCA) as an imaging …

    Published on 5/2/2016
  • Adimab, Takeda deal

    Adimab LLC, Lebanon, N.H. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Antibodies Adimab will use its yeast-based discovery and optimization platform or its B cell sorting capabilities to identify…

    Published on 5/2/2016
  • Affibody, Swedish Orphan Biovitrum deal

    Affibody AB, Stockholm, Sweden Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Business: Inflammation Swedish Orphan exercised its option under a 2012 deal to develop treatments for inflammatory diseases where…

    Published on 5/2/2016
  • Ascentage, Unity Biotechnology deal

    Ascentage Pharma Group Corp. Ltd., Hong Kong, China Unity Biotechnology, San Francisco, Calif. Business: Other Unity and Ascentage partnered to develop small molecules to treat age-related diseases by selectively …

    Published on 5/2/2016
  • AstraZeneca, Ironwood deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Business: Endocrine/Metabolic AstraZeneca granted Ironwood exclusive, U.S. rights to Zurampic lesinurad, …

    Published on 5/2/2016
  • Aviragen, HealthCare Royalty Partners deal

    Aviragen Therapeutics Inc. (NASDAQ:AVIR), Alpharetta, Ga. HealthCare Royalty Partners, Stamford, Conn. Business: Infectious Aviragen sold an undisclosed portion of its Inavir laninamivir octanoate royalty rights to …

    Published on 5/2/2016
  • biOasis, Astellas deal

    biOasis Technologies Inc. (TSX-V:BTI;OTCQB:BIOAF), Vancouver, B.C. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Drug delivery biOasis and Astellas Astellas Research Institute of America LLC unit partnered …

    Published on 5/2/2016
  • Cancer Research UK, University of Copenhagen, ADC Therapeutics deal

    Cancer Research UK, London, U.K. University of Copenhagen, Copenhagen, Denmark ADC Therapeutics S.a.r.l., Epilanges, Switzerland Business: Cancer Cancer Researchs Cancer Research Technology subsidiary and the university…

    Published on 5/2/2016
  • Cao Pharmaceuticals, NanoMaterials deal

    Cao Pharmaceuticals Inc., Houston, Texas NanoMaterials Technology Pte. Ltd., Singapore Business: Cancer Cao granted NanoMaterials NMT Pharmaceuticals Pte. Ltd. subsidiary exclusive, worldwide rights to develop and …

    Published on 5/2/2016
  • Charles River, BioMotiv deal

    Charles River Laboratories International Inc. (NYSE:CRL), Wilmington, Mass. BioMotiv LLC, Cleveland, Ohio Business: Supply/Service Charles River and BioMotiv partnered to advance candidates sourced from academia and …

    Published on 5/2/2016
  • Crelux, New WuXi deal

    Crelux GmbH, Martinsried, Germany New WuXi Life Science Ltd., Shanghai, China Business: Supply/Service New WuXis Wuxi AppTec subsidiary acquired structure-based drug discovery company Crelux. WuXi said the acquisition …

    Published on 5/2/2016
  • CytomX, AbbVie deal

    CytomX Therapeutics Inc. (NASDAQ:CTMX), South San Francisco, Calif. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer CytomX and AbbVie partnered to co-develop and co-commercialize Probody drug conjugates against …

    Published on 5/2/2016
  • Cytonet, Promethera deal

    Cytonet GmbH & Co. KG, Weinheim, Germany Promethera Biosciences S.A., Mont-Saint-Guibert, Belgium Business: Hematology, Hepatic Promethera acquired Cytonets key assets, including Heparesc and Cytonets HepaStem and …

    Published on 5/2/2016
  • Eli Lilly, Transition Therapeutics deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Transition Therapeutics Inc. (TSX:TTH;NASDAQ:TTHI), Toronto, Ontario Business: Endocrine/Metabolic Transition will regain rights to Type II diabetes compound TT401 from …

    Published on 5/2/2016
  • Enumeral Biomedical, Pieris Pharmaceuticals deal

    Enumeral Biomedical Holdings Inc. (OTCQB:ENUM), Cambridge, Mass. Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), Boston, Mass. Business: Cancer Enumeral granted Pieris exclusive, worldwide rights to IP related to its …

    Published on 5/2/2016
  • Evotec, ex scientia deal

    Evotec AG (Xetra:EVT), Hamburg, Germany ex scientia Ltd., Dundee, U.K. Business: Cancer The companies partnered to discover and develop bispecific small molecule immuno-oncology therapeutics. ex scientia will use its …

    Published on 5/2/2016
  • Hospital del Mar, University of Turin, Biocartis deal

    Hospital del Mar, Barcelona, Spain University of Turin, Turin, Italy Biocartis Group N.V. (Euronext:BCART), Mechelen, Belgium Business: Pharmacogenetics Hospital del Mar, via its Hospital del Mar Medical Research …

    Published on 5/2/2016
  • hVIVO, Seek Ltd. deal

    hVIVO plc (LSE:HVO), London, U.K. Seek Ltd., London, U.K. Business: Infectious hVIVO and Seek will form JV Imutex Ltd. to develop vaccines against the flu and mosquito-borne diseases. Seek will grant the JV worldwide …

    Published on 5/2/2016
  • Jiangsu Hengrui, Montefiore Medical Center deal

    Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276), Lianyungang, China Montefiore Medical Center, New York, N.Y. Business: Cancer Jiangsu Hengrui and Albert Einstein College, which is part of Montefiore, partnered to …

    Published on 5/2/2016
  • Kymab, Sosei deal

    Kymab Ltd., Cambridge, U.K. Sosei Group Corp. (Tokyo:4565), Tokyo, Japan Business: Cancer Kymab and Soseis Heptares Therapeutics Ltd. subsidiary partnered to discover, develop and commercialize antibodies against …

    Published on 5/2/2016
  • Medivation, Sanofi deal

    Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cancer Medivations board unanimously rejected an unsolicited offer from Sanofi to acquire the biotech for $52.…

    Published on 5/2/2016
  • Oxford BioTherapeutics, Boehringer Ingelheim deal

    Oxford BioTherapeutics Ltd., Abingdon, U.K. Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer Boehringer exercised a second option under a 2013 deal with Oxford and will receive exclusive rights to an …

    Published on 5/2/2016
  • PerkinElmer, Agency for Science, Technology and Research deal

    PerkinElmer Inc. (NYSE:PKI), Waltham, Mass. Agency for Science, Technology and Research, Singapore Business: Cancer PerkinElmer and A*STARs Genome Institute of Singapore (GIS) partnered to create PerkinElmer-GIS Centre …

    Published on 5/2/2016
  • Recursion Pharmaceuticals, Sanofi deal

    Recursion Pharmaceuticals LLC, Salt Lake City, Utah Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Pharmaceuticals Recursion and Sanofis Genzyme Corp. unit partnered to repurpose undisclosed small molecules …

    Published on 5/2/2016
  • Stemcentrx, AbbVie deal

    Stemcentrx Inc., South San Francisco, Calif. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer AbbVie will acquire Stemcentrx for about $2 billion in cash and $3.8 billion in stock. Stemcentrx shareholders are …

    Published on 5/2/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993